CURRENT AFFAIRS

Detailed explanation-1: -Covovax is manufactured by technology transfer from Novavax and is approved by the European Medicines Agency for conditional marketing authorisation and also granted emergency use listing by WHO on December 2017, 2020.

Detailed explanation-2: -Novavax COVID-19 Vaccine, Adjuvanted is available under emergency use authorization (EUA) to prevent COVID-19 in individuals 12 years of age and older. The vaccine is authorized for emergency use to provide: A two-dose primary series to individuals 12 years of age and older.

Detailed explanation-3: -Nuvaxovid (Novavax) is approved and available for use as a primary course in people aged 12 years and over. Novavax is approved and available for use as a booster in people aged 18 years and over. The TGA provisionally approved Novavax for use as a primary course in Australia on 20 January 2022.

Detailed explanation-4: -The FDA has authorized the emergency use of the Novavax COVID-19 Vaccine, Adjuvanted as a primary series to prevent COVID-19 in individuals 12 years of age and older and as a first booster dose in individuals 18 years of age and older under an EUA.

Detailed explanation-5: -U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults - Oct 19, 2022. Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.